AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02488564
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
Trial: NCT02488564
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
Trial: NCT02488564
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
Trial: NCT01516346
Drug: Isosorbide Dinitrate + Hydralazine
RxNorm normalized name: hydralazine / isosorbide dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
Trial: NCT05339295
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
Trial: NCT04486950
Drug: TAK-951
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-951 intravenous infusion.
Trial: NCT00490451
Drug: LY573636-sodium
RxNorm normalized name: LY573636
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
Trial: NCT00401375
Drug: Methylnaltrexone
RxNorm normalized name: Methylnaltrexone
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
Trial: NCT03513822
Drug: Ketamine 10 MG/ML
RxNorm normalized name: ketamine 10 MG/ML
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine infusion 1mg/kg with electric syringe during 2 hours.
Trial: NCT03513822
Drug: Midazolam 1 MG/ML
RxNorm normalized name: midazolam 1 MG/ML
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus of Midazolam 1mg before each perfusion.
Trial: NCT03170323
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
Trial: NCT00361569
Drug: DR-2041a
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
Trial: NCT00361569
Drug: DR-2041b
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
Trial: NCT03170323
Drug: Cyclosporins
RxNorm normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
Trial: NCT04523220
Drug: BAY1213790 (Osocimab)
RxNorm normalized name: Osocimab
DrugBank: Osocimab (DB14818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
Trial: NCT02605824
Drug: n-acetylcystine
DrugBank: Cystine (DB00138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC is a mucolytic drug.
Trial: NCT00796653
Drug: Olodaterol (BI 1744)
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of low and high doses on efficacy and safety in COPD patients
Trial: NCT00796653
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Trial: NCT00232102
Drug: Tegaserod
RxNorm normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01341730
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg QD for 3 months
Trial: NCT03699176
Drug: Vilaprisan (BAY1002670)
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg, once daily, oral
Trial: NCT01341730
Drug: Atorvastatin 20 mg + Pioglitazone 30 mg
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
Trial: NCT00481078
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00481078
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00481078
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00606203
Drug: milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
Trial: NCT00081159
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00081159
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01940341
Drug: TDF
RxNorm normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg tablet administered orally once daily
Trial: NCT01508702
Drug: lesinurad
RxNorm normalized name: Lesinurad
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, 400 mg QD
Trial: NCT02369432
Drug: Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03704467
Drug: M6620
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
Trial: NCT03704467
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
Trial: NCT03704467
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
Trial: NCT00697476
Drug: topotecan, vorinostat
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal.
Trial: NCT00514111
Drug: pegylated-interferon, conventional-interferon, ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
Trial: NCT02864368
Drug: 5-day TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle
Trial: NCT02864368
Drug: 21-day TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
Trial: NCT02030041
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D will be given to achieve normal serum levels
Trial: NCT00761514
Drug: Humira (adalimumab)
RxNorm normalized name: adalimumab Prefilled Syringe [Humira]
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg eow
Trial: NCT03615677
Drug: LXI-15028 50mg
RxNorm normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
Trial: NCT03615677
Drug: Esomeprazole 40mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
Trial: NCT00003105
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003105
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003105
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003105
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02124564
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~* 4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~* The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day.
Trial: NCT00217204
Drug: Pancrelipase microtablets
RxNorm normalized name: Pancrelipase amylase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00294359
Drug: Mitomycin C; Capecitabine; Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02136030
Drug: Liposomal amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg/kg/day, IV infusion
Trial: NCT02136030
Drug: Amphotericin B-deoxycholate
RxNorm normalized name: deoxycholate
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg/kg/day, IV infusion
Trial: NCT01430455
Drug: Tranylcypromine
RxNorm normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
Trial: NCT03402984
Drug: Acotiamide
RxNorm normalized name: acotiamide
DrugBank: Acotiamide (DB12482)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
Trial: NCT01884259
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² on day 1 of 21-days cycle
Trial: NCT01884259
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² on day 1 of 21-days cycle
Trial: NCT01884259
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
Trial: NCT04158076
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT01250912
Drug: 123I-metaiodobenzylguanidine
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
Trial: NCT00532077
Drug: rhPTH(1-34)
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00532077
Drug: SB-751689 100 mg
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00532077
Drug: SB-751689 400 mg
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03490058
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
Trial: NCT00773253
Drug: Botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
Trial: NCT04158076
Drug: Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET
RxNorm normalized name: telmisartan/amlodipine 80 mg-5 mg ORAL TABLET
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT00116350
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mcg sublingual misoprostol
Trial: NCT00116350
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 IU Oxytocin IV
Trial: NCT01353040
Drug: AVI-6003
RxNorm normalized name: AVI-4065
DrugBank: AVI-4065 (DB05620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration
Trial: NCT03587220
Drug: Capsaicin Topical
RxNorm normalized name: capsaicin topical
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
Trial: NCT03587220
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
Trial: NCT03773562
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erenumab will be used per label instructions.
Trial: NCT00616122
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03180099
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
Trial: NCT03180099
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml %0.1 Bupivacaine administered to Epidural Space
Trial: NCT02883023
Drug: Intralesional bleomycin injection
RxNorm normalized name: bleomycin Injection
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local intralesional injections with bleomycin
Trial: NCT00002831
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally every 6 hours on consecutive days -6 through -4.
Trial: NCT00002831
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
Trial: NCT00002831
Drug: Decitabine (DAC)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV over 4 hours on days -8 and -7.
Trial: NCT00002831
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given according to clinical grade of GVHD procedures.
Trial: NCT00002831
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
Trial: NCT02122198
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
Trial: NCT02122198
Drug: Medroxyprogesterone
RxNorm normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
Trial: NCT02530905
Drug: SRP-4045
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP-4045 solution for IV infusion.
Trial: NCT02982954
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified day
Trial: NCT02982954
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified Dose on Specified Day
Trial: NCT02478047
Drug: only antiemetic (Ramosetron, Tropisetron and dexamethasone)
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
Trial: NCT02208128
Drug: Sunitinib, Pazopanib, Bevacizumab, Everolimus...
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Clinical standard
Trial: NCT01998295
Drug: Artemether/lumefantrine
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.